"10.1371_journal.pone.0060463","plos one","2013-04-02T00:00:00Z","Batu K Sharma-Kuinkel; Yurong Zhang; Qin Yan; Sun Hee Ahn; Vance G Fowler","Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America; Duke Clinical Research Institute, Durham, North Carolina, United States of America","Conceived and designed the experiments: BKSK SHA VGF. Performed the experiments: BKSK SHA. Analyzed the data: BKSK SHA. Contributed reagents/materials/analysis tools: BKSK YZ QY SHA. Wrote the paper: BKSK SHA VGF.","The authors have read the journal’s policy and have the following conflicts. V.G.F. has received grants or research support from Astellas Pharma, Inc., Cubist Pharmaceuticals, Merck & Co., Inc., Theravance, Inc., MedImmune, Cerexa, Inc., Pfizer, Advanced Liquid Logic, MedImmune and the United States National Institutes of Health. He is a consultant for Astellas Pharma, Inc., Biosynexus, Novartis, Cubist Pharmaceuticals, Inimex, Merck & Co., Inc., Galderma, Johnson & Johnson, Medicines Company, Novartis and is on the speaker’s bureau and advisory committee for Cubist Pharmaceuticals. He has received honoraria from Achaogen, Arpida, Astellas Pharma, Inc., Cubist Pharmaceuticals, Durata, Inhibitex, Leo Pharma, Merck & Co., Inc., Pfizer, Targanta, Theravance, Inc., and Ortho-McNeil. This study uses Linezolid, a product produced by Pfizer, Inc. The co-author V.G.F. is a PLOS ONE Editorial Board member. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. B.K.S.K, Y.Z., Q.Y. and S.H.A. have no competing interests to declare.","2013","04","Batu K Sharma-Kuinkel","BKSK",5,FALSE,3,2,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
